Skip to main content

Eye Infection

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Moxifloxacin ophthalmic solution 0.5%Phase 41 trial
Active Trials
NCT00347828Unknown40Est. Jun 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieMoxifloxacin ophthalmic solution 0.5%

Clinical Trials (1)

Total enrollment: 40 patients across 1 trials

NCT00347828AbbVieMoxifloxacin ophthalmic solution 0.5%

Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose

Start: Jun 2006Est. completion: Jun 200640 patients
Phase 4Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.